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Summary The scale-up of antiretroviral therapy (ART) has been one of the success stories of sub-Saharan Africa,
where coverage has increased from about 2% in 2003 to more than 40% 5 years later. However,
tempering this success is a growing concern about patient retention (the proportion of patients who are
alive and remaining on ART in the health system). Based on the personal experience of the authors, 10
key interventions are presented and discussed that might help to improve patient retention. These are (1)
the need for simple and standardized monitoring systems to track what is happening, (2) reliable
ascertainment of true outcomes of patients lost to follow-up, (3) implementation of measures to reduce
early mortality in patients both before and during ART, (4) ensuring uninterrupted drug supplies,
(5) consideration of simple, non-toxic ART regimens, (6) decentralization of ART care to health
centres and the community, (7) a reduction in indirect costs for patients particularly in relation to
transport to and from clinics, (8) strengthening links within and between health services and the
community, (9) the use of ART clinics to deliver other beneficial patient or family-orientated packages of
care such as insecticide-treated bed nets, and (10) innovative (thinking ‘out of the box’) interventions.
High levels of retention on ART are vital for individual patients, for credibility of programmes and for
on-going resource and financial support.
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Introduction
The massive and unprecedented scale-up of antiretroviral
therapy (ART) in low and middle income countries in the
last 5 years is probably the most outstanding achievement
in the global fight against HIV ⁄AIDS, where estimated
numbers started on therapy have risen from 400 000 in
2004 to 4 million by the end of 2008 (WHO et al. 2009) In
sub-Saharan Africa alone, 2.9 million patients were esti-
mated to be receiving ART by December 2008, compared
with about 25 000 in 2002. Tempering this success,
however, is a growing concern about patient retention
(patients who are alive and remaining on ART in the health
system). A systematic review of ART programmes in sub-
Saharan Africa in 2007 indicated that only 60% of patients
were retained on therapy 2 years after starting ART, with
deaths and losses to follow-up being the major causes of
attrition (Rosen et al. 2007). In the real world of resource-
constrained public health agencies and facilities, what can
be done? Based on our personal experience with ART
scale-up in Africa in government and mission health care
facilities combined with research on ART programmes, we
present 10 practical interventions that we believe can
improve patient retention.
1. Set up and maintain simple, standardized
monitoring systems
Every facility that provides ART must set up a simple,
standardized monitoring system to track the numbers of
patients starting therapy every month or every quarter and
to determine at the end of every quarter five key
standardized outcomes – those who are alive and on
therapy, those who are dead, those who are known to have
stopped treatment, those who have transferred out to
another facility, and those who have been lost to follow-up
or ‘defaulted’. Being alive and on therapy implies retention
in care. Formal transfer outs from one facility to another
are common as the number of facilities expands and
patients seek treatment closer to home. Patients who
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transfer from one facility to another are still considered as
being retained on ART in the health system, but only if
they can be tracked to their new facility through linked
record-keeping systems.
Reliable and regular reports of retention and attrition
are carried out every 3 months, for example, in the
resource-poor country of Malawi, where each facility
performs its own quarterly and cumulative cohort out-
come analysis with results checked and collated as a
result of quarterly supervision and monitoring visits from
Ministry of Health personnel and partners (Libamba
et al. 2006). Treatment outcomes and their dates (or
nearest month in which the outcome occurred) are
rigorously recorded. This is labour intensive, and medical
officers in charge of facilities have to allow staff sufficient
time to complete the record-keeping and analysis. Good
quality work should be rewarded, e.g. in Malawi,
quarterly certificates of excellence are awarded to ART
clinics for good record keeping of treatment cards and
registers and accurate quarterly and cumulative outcome
reports.
Unfortunately, and although carried out with the best
of intentions, there is a tendency for donor-supported
programmes to demand large amounts of data that relate
to demographic and clinical features, adverse events, and
biochemical and immunological tests. The predictable
results in resource-constrained settings are poorly
completed forms, incomplete data sets, and unreliable
data on what counts, namely retention on therapy and
attrition. ART programme designers and managers
should resist this pressure, as timely collection of reliable
data on the five standardized outcomes is hard enough to
achieve on its own without over-loading the often
manual monitoring system with a host of other param-
eters. This simple approach is vindicated by recent data
from the Development of Antiretroviral Therapy in
Africa (DART) trial in Uganda and Zimbabwe showing
that treatment outcomes in the short to medium term are
as good with simple clinical monitoring compared with
clinical and laboratory monitoring (DART Trial Team
2010).
Electronic medical record systems can play an important
role, particularly as numbers of patients and treatment sites
increase. Experience from a wide range of sites across
Africa has shown that for this to work properly, however,
adequate human resources and staff training are essential
(Forster et al. 2008). Moreover, appropriate, standardized
soft-ware packages need to be developed to facilitate the
use and expansion of this resource and to avoid the
scenario of having as many different electronic information
systems in use as there are administrative districts, NGO
partners, or funding agencies.
2. Reliably ascertain true treatment outcomes
Good ART clinic practices must include reliable ascer-
tainment of outcomes of death, stopped treatment and loss
to follow-up (attrition parameters), and the formal
recording of transfer outs from one ART facility to
another. Death may be ascertained pro-actively by a
relative or friend providing information to the clinic, or it
may be discovered as part of active tracing of patients who
fail to attend their clinic appointment. In some countries,
national death registers can also be used, if available.
Similarly, patients who have stopped therapy may inform
the clinic, but it is more likely that this information will be
discovered through active tracing. Patient transfers need to
be structurally managed, through formal recording,
otherwise these patients may also be recorded as lost to
follow-up. Thus, the ascertainment of true outcomes is a
crucial programmatic activity.
In Malawi, as in many other African countries, patients
are classified as lost to follow-up if they fail to attend clinic
or obtain medications for 3 months or more. In an
operational research study in Northern Malawi to deter-
mine the true outcomes of these patients, 50% had died,
15% had stopped therapy, and 8% had transferred to
another clinic and failed to inform their original clinic of
this move (Yu et al. 2007). The results of this study were
confirmed in a recent systematic review and meta-analysis
(16 studies from sub-Saharan Africa), showing that 20% to
60% of patients who had been recorded as lost to follow-
up had died (Brinkhof et al. 2009).
Patients who are lost to follow-up can be identified
through regular scrutiny of paper-based treatment cards or
use of electronic data-base systems. Pharmacy-based
records of medication collection by patients can also be
used to monitor patient retention (Nachega et al. 2006;
Wood et al. 2008). Electronic pharmacy records in par-
ticular may provide an efficient means of generating lists of
patients who have failed to pick up medication and who
can then potentially be traced in the community. For
example, iDART is a computerized software that requires
no licence and is freely available to download at URL
http://www.cell-life.org/idart/download/. This system
allows easy management and follow-up of patients by
pharmacists and programme management teams and has
already been successfully used in seven large-scale ART
programmes within four provinces in South Africa (Wood
et al. 2008).
Clinics will vary in terms of their ability to trace patients
who are either late for their appointment or who have been
recorded as lost to follow-up. Well-resourced clinics that
are not overly burdened with high patient loads may have
outreach teams that can trace patients and reduce their loss
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to follow-up rate. Poorly resourced clinics cannot do this,
but correct recording of addresses or the location of homes
within villages or towns, using community networks, and
tapping in to the expanding cell phone networks (Lester
et al. 2006) should all be used to try and maintain patient
contact. Where possible it is essential to conduct opera-
tional research to investigate and address the reasons for
patient attrition, particularly deaths and loss to follow-up.
3. Reduce death rates
The ART-lower income country (ART-LINC) collabora-
tion compared treatment outcomes from 18 ART
programmes in lower-income settings (predominately in
Africa) with those of 12 HIV cohort studies from Europe
and North America and found that early mortality after
initiation of ART was several times higher in resource-
limited settings (Braitstein et al. 2006). From 8% to 26%
of patients die in the first year of ART in African settings,
with most deaths occurring in the first few months after
starting treatment (Lawn et al. 2008). Risk factors for
early deaths include low baseline CD4 lymphocyte count,
initiation of therapy when already in WHO clinical stage 4,
low body mass index and anaemia, with the main
responsible diseases being tuberculosis (both diagnosed
and undiagnosed), bacterial sepsis, cryptococcal meningitis
and Kaposi’s sarcoma. Useful interventions to reduce this
early mortality that should be implemented either before or
simultaneously with initiation of ART include cotrimox-
azole preventive therapy (Lowrance et al. 2007), active
screening for tuberculosis among high-risk patients such as
those with unexplained weight loss and ⁄or unexplained
chronic fever, and screening for those at high risk of
cryptococcal meningitis with cryptococcal antigen testing
and targeted pre-emptive treatment for those with positive
results (Jarvis et al. 2009).
There seems little doubt that the cumulative risk of dying
before and during ART is strongly associated with time
spent at low CD4 counts (Lawn et al. 2009). At the end of
2009, WHO issued revised international ART guidelines
for resource-limited settings recommending that all adults
and adolescents with WHO Stage 3 and 4 disease and all
those with a CD4 count < 350 cells ⁄uL should receive
ART (WHO 2009). However, for this to make much
difference to patient management, there needs to be far
better access to CD4 count testing, which will probably
only happen when simple, inexpensive, point-of-care CD4
tests become available. The concept of ‘pre-ART’ care also
needs to be championed. A package of regular care and
support, which includes community awareness and
empowerment, clinical assessment, CD4 count measure-
ment and cotrimoxazole and isoniazid preventive therapy,
for HIV-infected patients not yet eligible for ART would
greatly assist in decreasing subsequent late presentation
and high early mortality on ART (Lawn et al. 2010).
4. Ensure uninterrupted ART drug supplies
There must be no stock-outs of ART drug supplies, so that
health care worker and patient confidence in the system is
maintained. Accurate drug forecasting is dependent on
data, and for those alive and on therapy, it is crucial to
know what regimen (first line or second line) the patient is
taking. The data recording exercise should be kept as
simple as possible with those alive and on therapy stratified
by type of regimen. ART programmes should prioritize a
few standardized regimens that are offered at all ART
facilities, with more sophisticated, tailor-made treatments
being limited to centres of excellence. Electronic pharmacy-
based systems would greatly assist in these endeavours.
Linking the data system with drug forecasting and
procurement was the approach adopted for national drug
procurement during the first 4 years of ART scale up in
Malawi, during which time there were no national or
facility stock-outs (Harries et al. 2007). Secure drug
supplies help to enhance credibility of the health facility
and mitigate attrition from therapy.
5. Use simple, non-toxic, and free ART regimens
ART regimens need to be as non-toxic and simple to take
as possible, and they must be offered free-of-charge to the
patient. The most commonly used and least expensive ART
regimen in resource-limited settings, especially in sub-
Saharan Africa, is a fixed-dose drug combination of
stavudine + lamivudine + nevirapine (Renaud-Thery et al.
2007). While not optimal in terms of tolerability or
concurrent use with TB treatment, the ease of regimen
administration allows the therapy to be given by para-
medical staff, lay providers and expert patients in poorly
staffed facilities. Stavudine is responsible for considerable
late toxicity, but there are still limited alternatives in
Africa. Recent research studies have demonstrated that a
reduced dose of 30 mg twice daily for all patients is
associated with good viral efficacy and a lower incidence of
side effects (Ait-Mohand et al. 2008), and most African
ART programmes now only use this lower dose. The WHO
recommends the phasing out of stavudine and replacement
with less toxic but more expensive alternatives, such as
tenofovir (World Health Organization 2009), and if this
can be carried out it should improve adherence.
Studies in Kenya (Zachariah et al. 2008) and
Cameroon (Boyer et al. 2009), as well as cohort meta-
analyses (Braitstein et al. 2006; Brinkhof et al. 2008),
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have all clearly shown that payment for ART drugs is
associated with higher rates of death and loss to
follow-up compared with drugs given free-of-charge.
This evidence has led to policy change and a clear
recommendation by the WHO that access to HIV ⁄ART
treatment at the point of service delivery should be free
(Souteyrand et al. 2008).
6. Decentralize ART clinics and reduce frequency of
visits for stable patients
ART clinics have to be brought nearer to patients’ homes,
and thus ART care has to be decentralized to rural
hospitals and health centres. This means task shifting, and
the responsibility for the provision of ART care moving
from doctors, to nurses, to paramedical officers and even to
expert patients (Philips et al. 2008). Decentralization and
task shifting has been shown to work in rural settings in
both Malawi and Uganda (Jaffar et al. 2009; Massaquoi
et al. 2009). The demand on patients to attend health
facilities for drug pick-ups and clinical assessments must
also be reduced. This can be achieved either by reducing
follow-up visits to health facilities to once every 2 or
3 months or by providing home-based care through com-
munity nurses, expert patients or volunteers, home-based
care being both feasible and cost-effective in rural settings
(Jaffar et al. 2009). Another option that may be feasible in
some countries is to allow non-medical facilities, such as
schools or local government offices, to distribute pre-
packaged drugs that have been labelled in advance by a
central pharmacy.
7. Reduce indirect patient costs
Lifelong ART is demanding for patients, and attempts must
be made to reduce and minimize indirect patient costs, for
example, for transport or time spent out of the work place.
Despite provision of free ART in poor South African
townships, socioeconomic status within these communities
remains a powerful predictor of risk of death or loss to
follow-up (Cornell et al. 2009). Many patients have no
income and have to choose, for example, between the
providing food for their family or transport to the ART
clinic. Similarly in Malawi, high transport costs have been
associated with lower acceptance rates of ART among
tuberculosis patients in rural communities and higher rates
of loss to follow-up (Zachariah et al. 2006). Solutions
include socio-economic interventions such as reimburse-
ment for transport costs, decentralization of services within
communities or home-based care, the latter being less
expensive for patients compared with travel to clinics
(Jaffar et al. 2009).
8. Strengthen ART links within and between the health
service and the community
It is important to consider integration and streamlining of
health services so that patients do not get lost within the
general health system. For example, there was a high loss
to follow-up of HIV-infected pregnant women who were
referred to a community ART clinic in South Africa
(Kaplan et al. 2008), part of the reason being difficulties
experienced by the women in attending separate antenatal,
ART and paediatric clinics. The same problem is con-
fronted by HIV-infected tuberculosis patients, who often
have to attend separate tuberculosis and ART clinics for
monitoring and drug collection.
Every attempt must be made by ART clinics to link their
services with the community, and particularly with asso-
ciations of people living with HIV ⁄AIDS. In rural Malawi,
care packages such as home treatment of opportunistic
infections, support to family carers, referral of patients
with adverse drug reactions, adherence counselling and
defaulter tracing have, not surprisingly, been associated
with better ART treatment outcomes (Zachariah et al.
2007). In a large ART service within a poor South African
township, a peer counsellor system has contributed to
comparatively low rates of mortality and loss to follow-up
(Lawn et al. 2006, 2007). These are all win–win solutions
for patient retention in the face of the human resources
crisis in Africa.
9. Use ART services to deliver other useful
interventions
In Uganda, the provision of cotrimoxazole and insecticide-
treated bed nets in addition to ART resulted in a
considerable reduction in frequency of malaria attacks
(Mermin et al. 2006). In Malawi, pilot studies demon-
strated the feasibility of providing insecticide-treated bed
nets through routine ART clinics, and this service was
very popular with patients and health care providers
(Makombe et al. 2007). There needs to be a degree of
flexible thinking, followed by firm commitments, to use the
ART programme as an opportunity to improve holistic
linkages and provide additional services such as
nutritional support and family planning, all of which may
encourage better retention on treatment. Chronic, non-
communicable diseases such as diabetes mellitus and
hypertension are becoming important additional causes of
morbidity and mortality in rural and urban settings in
Africa (Tollman et al. 2008). The principles and practices
of providing life long chronic structured care are being
learnt from ART programmes (Harries et al. 2009), and
it makes sense to provide integrated chronic care for
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infectious and non-infectious diseases together. Models
already exist, for example a chronic care clinic in
Cambodia that provided structured treatment for patients
with HIV ⁄AIDS, diabetes mellitus and hypertension
(Janssens et al. 2007).
10. Innovative (thinking ‘out of the box’) interventions
It will be crucial as the burden of patients on ART grows to
think out of the box about how to support life-long
adherence to medication and compliance with follow-up.
This could include interventions such as twice daily radio
announcements reminding patients to take their medica-
tion; ART stations at work places; and pick-ups of pre-
packaged ART from local general supply stores, schools, or
community-based ART refill sites rather than always from
the clinic. These new modes of delivery, which will
inevitably involve loss of control from the medical
profession, will need to be piloted and tested through
operational research.
In conclusion, the initial enthusiasm for ART scale-up
may be threatened if ART retention rates are poor or
progressively deteriorate. The international donor com-
munity will want to see its money well spent, and it is
therefore beholden on ART programmes to collect the
necessary data and to use all measures possible to ensure
high retention and adherence to therapy.
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